Moharem El Gihani

Moharem El Gihani has over a decade of experience in business development, primarily in the pharmaceutical and biotech industries. Moharem is currently serving as the Vice President of Business Development for X-Chem, Inc. in the UK and Europe. Prior to this role, they worked as the Business Development Lead for Piramal Pharma Solutions in Europe from 2018 to 2021.

From 2014 to 2018, Moharem was the founder of Silphium Ventures, where they provided consulting services in business development, business strategy, and financial modeling within the healthcare sector. Moharem also focused on innovative finance solutions for biotech and healthcare, leveraging their expertise in sovereign wealth and social investment.

Moharem has held various positions in business development, including VP Business Development for Cambridge Rare Disease Network (2015-2017), VP Business Development for Seven Bridges (2016), and VP Business Development for Cyclofluidic Ltd. (2015). Moharem was also the Chief Business Development Officer for Innovation Forum (2014-2015).

Furthermore, Moharem gained experience in business development and finance during their time at Cambridge University Student Consulting Group (CUSCG) as a Business Development & CFO from 2013 to 2014. Moharem was part of the winning team for the National Institutes of Health (NIH) Breast Cancer Startup Challenge, where they developed a business plan on using Virus-like Particles (VLPs) for cancer therapeutics.

Earlier in their career, Moharem worked as an Associate Director in Business Development for Sai Advantium Pharma Ltd from 2008 to 2012 and as the Business Development Director for Cambridge Research Biochemicals in 2007.

Overall, Moharem El Gihani has a diverse background in business development and strategy, with a specific focus on the pharmaceutical and biotech sectors.

Moharem El Gihani's education history is as follows:

Moharem completed their Master of Business Administration (MBA) degree with a specialization in Dissertation: Sovereign Wealth Fund (SWF) Investment in Biotech-focused Venture Capital from LAIBS, Cambridge from 2012 to 2014.

Prior to that, from 1997 to 1999, they pursued a Post Doc degree in Organic Chemistry at the University of Bath.

Before that, they obtained a Doctor of Philosophy (PhD) degree in Organic Chemistry from Loughborough University from 1992 to 1996.

In 1991 to 1992, they completed their MSc degree with a focus on Medicinal Chemistry & Drug Metabolism at Loughborough University.